Nature Communications (Mar 2018)
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1
- Gonzalo Hernández,
- María José Ramírez,
- Jordi Minguillón,
- Paco Quiles,
- Gorka Ruiz de Garibay,
- Miriam Aza-Carmona,
- Massimo Bogliolo,
- Roser Pujol,
- Rosario Prados-Carvajal,
- Juana Fernández,
- Nadia García,
- Adrià López,
- Sara Gutiérrez-Enríquez,
- Orland Diez,
- Javier Benítez,
- Mónica Salinas,
- Alex Teulé,
- Joan Brunet,
- Paolo Radice,
- Paolo Peterlongo,
- Detlev Schindler,
- Pablo Huertas,
- Xose S Puente,
- Conxi Lázaro,
- Miquel Àngel Pujana,
- Jordi Surrallés
Affiliations
- Gonzalo Hernández
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona
- María José Ramírez
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona
- Jordi Minguillón
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona
- Paco Quiles
- Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Gorka Ruiz de Garibay
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L’Hospitalet del Llobregat
- Miriam Aza-Carmona
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona
- Massimo Bogliolo
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona
- Roser Pujol
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona
- Rosario Prados-Carvajal
- Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER) and Departamento de Genética, Universidad de Sevilla
- Juana Fernández
- Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Nadia García
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L’Hospitalet del Llobregat
- Adrià López
- Hereditary Cancer Programme, ICO, Girona Biomedical Research Institute (IDIBGI)
- Sara Gutiérrez-Enríquez
- Oncogenetics Group, Vall d´Hebron Institute of Oncology (VHIO)
- Orland Diez
- Oncogenetics Group, Vall d´Hebron Institute of Oncology (VHIO)
- Javier Benítez
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)
- Mónica Salinas
- Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Alex Teulé
- Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Joan Brunet
- Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Paolo Radice
- Department of Preventive and Predictive Medicine, Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT)
- Paolo Peterlongo
- Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Unit of Molecular Bases of Genetic Risk and Genetic Testing
- Detlev Schindler
- Department of Human Genetics, Wurzburg University
- Pablo Huertas
- Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER) and Departamento de Genética, Universidad de Sevilla
- Xose S Puente
- Department of Biochemistry and Molecular Biology, Instituto Universitario de Oncología, Universidad de Oviedo
- Conxi Lázaro
- Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat
- Miquel Àngel Pujana
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L’Hospitalet del Llobregat
- Jordi Surrallés
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona
- DOI
- https://doi.org/10.1038/s41467-018-03433-3
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
Mutations in BRCA1 are associated with an increased risk of breast and ovarian cancer. Here the authors show that EDC4, a component of P-bodies, is a member of the BRCA1 complex with roles in stimulating end resection at breaks.
